Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital discharge alive by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in hospital discharge alive by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
 · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in  compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
OS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention leads to lower OS (at 3 years) (high certainty).
1 finding from 1 review
Intervention not reported
TRM · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in TRM (low certainty).
1 finding from 1 review
Intervention not reported
PFS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention probably leads to lower PFS (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
TRM · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in TRM (moderate certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in SAEs ‐ overall analysis (low certainty).
1 finding from 1 review
Intervention not reported
Grade 3/4 AEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL
The intervention probably leads to higher grade 3/4 AEs ‐ overall analysis (moderate certainty).
1 finding from 1 review
Intervention not reported
OS not reported · newly diagnosed or relapsed patients with CLL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
PFS not reported · newly diagnosed or relapsed patients with CLL
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Time to next treatment · newly diagnosed or relapsed patients with CLL
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
CRR · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in CRR (moderate certainty).
1 finding from 1 review